발프로산은 가장 보편적으로 사용되는 항간질제로서 약제 유발성 췌장염의 흔한가능한 원인으로 잘 알려져 있다. 그 러나 발프로산 유발성 췌장염의 유해사례로서발프로산 유 발성 췌장염의 국소 합병증으로서 췌장 가성낭종은 매우 드 물며 주로 소아청소년기에 호발한다고 알려져 있다. 또한 이로 인한 발프로산 유발성 췌장염에 병발된 출혈성 가성낭종 은 보고된 증례가 없을 정도로 드물다. 이에 본 저자들은 발 프로산을 복약한 후 발생한 급성 출혈성 췌장 가성낭종을 경 피적 배액술로 성공적으로 치료한 증례를 보고하고자 한다.

Cells that have endogenous multipotent properties can be used as a starting source for the generation of induced pluripotent cells (iPSC). In addition, small molecules associated with epigenetic reprogramming are also widely used to enhance the multi- or pluripotency of such cells. Skinderived precursor cells (SKPs) are multipotent, sphereforming and embryonic neural crest-related precursor cells. These cells can be isolated from a juvenile or adult mammalian dermis. SKPs are also an efficient starting cell source for reprogramming and the generation of iPSCs because of the high expression levels of Sox2 and Klf4 in these cells as well as their endogenous multipotency. In this study, valproic acid (VPA), a histone deacetylase (HDAC) inhibitor, was tested in the generation of iPSCs as a potential enhancer of the reprogramming potential of SKPs. SKPs were isolated from the back skins of 5-6 week old C57BL/6 X DBA/2 F1 mice. After passage 3, the SKPs was treated with 2 mM of VPA and the quantitative real time RT-PCR was performed to quantify the expression of Oct4 and Klf4 (pluripotency specific genes), and Snai2 and Ngfr (neural crest specific genes). The results show that Oct4 and Klf4 expression was decreased by VPA treatment. However, there were no significant changes in neural crest specific gene expression following VPA treatment. Hence, although VPA is one of the most potent of the HDAC inhibitors, it does not enhance the reprogramming of multipotent skin precursor cells in mice.